Association between Leflunomide and Pulmonary Hypertension

T. Lacoste Palasset (Le Kremlin Bicêtre, France), M. Chaumais (Le Kremlin Bicêtre, France), J. Weatherald (Calgary, Canada), L. Savale (Le Kremlin Bicêtre, France), X. Jaïs (Le Kremlin Bicêtre, France), L. Price (London, United Kingdom), C. Khouri (Grenoble, France), S. Bulifon (Le Kremlin Bicêtre, France), A. Seferian (Le Kremlin Bicêtre, France), M. Jevnikar (Le Kremlin Bicêtre, France), A. Boucly (Le Kremlin Bicêtre, France), G. Manaud (Le Plessis-Robinson, France), S. Pancic (Calgary, France), C. Chabanne (Rennes, France), K. Ahmad (Lyon, France), M. Volpato (Montpellier, France), N. Favrolt (Dijon, France), A. Guillaumot (Vandoeuvre-lès-Nancy, France), D. Horeau-Langlard (Nantes, France), G. Prévot (Toulouse, France), P. Fesler (Montpellier, France), L. Bertoletti (Saint-Etienne, France), M. Reynaud-Gaubert (Marseille, France), N. Lamblin (Lille, France), D. Launay (Lille, France), G. Simonneau (Le Kremlin Bicêtre, France), O. Sitbon (Le Kremlin Bicêtre, France), F. Perros (Le Plessis-Robinson, France), M. Humbert (Le Kremlin Bicêtre, France), D. Montani (Le Kremlin Bicêtre, France)

Source: Virtual Congress 2021 – All about pulmonary arterial hypertension
Session: All about pulmonary arterial hypertension
Session type: Oral Presentation
Number: 146

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Lacoste Palasset (Le Kremlin Bicêtre, France), M. Chaumais (Le Kremlin Bicêtre, France), J. Weatherald (Calgary, Canada), L. Savale (Le Kremlin Bicêtre, France), X. Jaïs (Le Kremlin Bicêtre, France), L. Price (London, United Kingdom), C. Khouri (Grenoble, France), S. Bulifon (Le Kremlin Bicêtre, France), A. Seferian (Le Kremlin Bicêtre, France), M. Jevnikar (Le Kremlin Bicêtre, France), A. Boucly (Le Kremlin Bicêtre, France), G. Manaud (Le Plessis-Robinson, France), S. Pancic (Calgary, France), C. Chabanne (Rennes, France), K. Ahmad (Lyon, France), M. Volpato (Montpellier, France), N. Favrolt (Dijon, France), A. Guillaumot (Vandoeuvre-lès-Nancy, France), D. Horeau-Langlard (Nantes, France), G. Prévot (Toulouse, France), P. Fesler (Montpellier, France), L. Bertoletti (Saint-Etienne, France), M. Reynaud-Gaubert (Marseille, France), N. Lamblin (Lille, France), D. Launay (Lille, France), G. Simonneau (Le Kremlin Bicêtre, France), O. Sitbon (Le Kremlin Bicêtre, France), F. Perros (Le Plessis-Robinson, France), M. Humbert (Le Kremlin Bicêtre, France), D. Montani (Le Kremlin Bicêtre, France). Association between Leflunomide and Pulmonary Hypertension. 146

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pulmonary Hypertension
Source: Research Seminar 2013 - Optimising models for human lung diseases and drug development
Year: 2013


Pulmonary Hypertension
Source: Eur Respir Rev 2009; 18: 193-194
Year: 2009


Clinical efficacy of Macitentan in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018

Pulmonary Hypertension in Childhood
Source: Virtual Congress 2020 – From the bronchoscope to the clinic: paediatric bronchology at a glance
Year: 2020


Clinical Features of Pulmonary Hypertension
Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease
Year: 2012


Epoprostenol dosing by concomitant therapies in the PROSPECT registry
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014

Innovative therapies in Pulmonary Hypertension
Source: ERS Research Seminar 2016 - Pulmonary Vascular Endothelium: Orchestra Conductor in Respiratory Diseases - Highlights from Basic Research to Therapy
Year: 2016


Impact of Pulmonary Hypertension on the Response to Pulmonary Rehabilitation in Obstructive Lung Disease
Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today
Year: 2019


Nebivolol and pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014

Pulmonary Arterial Hypertension Research Award
Source: Annual Congress 2008 - Pulmonary Arterial Hypertension Research Award (supported by Actelion Pharmaceuticals)
Year: 2008


Pulmonary Arterial Hypertension Research Award
Source: Annual Congress 2009 - Pulmonary Arterial Hypertension Research Award (supported by Actelion Pharmaceuticals)
Year: 2009


Pulmonary Hypertension and IPF?
Source: Virtual Congress 2021 – Pulmonary hypertension and interstitial pulmonary fibrosis
Year: 2021

Interventional Treatment in Chronic Thromboembolic Pulmonary Hypertension with Microvasculopathy
Source: Virtual Congress 2020 – Pulmonary embolism and beyond
Year: 2020


Effects on Right Ventricular size and function by Riociguat in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension (The RIVER Study)
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018

Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021


Treatment of Chronic Thromboembolic Pulmonary Hypertension: A new approach
Source: International Congress 2018 – CC2 Broad spectrum of chronic thromboembolic pulmonary hypertension
Year: 2018